Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
Active, not recruiting · NCT05254314 · Registry updated 2026-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) | Body Weight, Hypersensitivity, Immediate, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Respiratory Hypersensitivity, Signs and Symptoms, asthma, bronchial disorder, immune system disorder, lung disorder, nutritional disorder, obesity disorder, obstructive lung disease, overnutrition, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-10-01 | NCT05254314 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 402 |
| Vanderbilt University Medical Center | 299 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Vanderbilt University Medical Center | Nashville | United States | 40 |